STAT+: FDA to reconsider treatment for rare cancer after surprise rejection

The FDA is set to reconsider a treatment for rare cancer after a surprise rejection. The Trump administration claims massive savings from secret drug pricing deals. FDA leadership faces accusations of political interference in drug reviews.